Polomar Loses Two Directors in One Day, Board Cut From Five to Three
PMHS sits 85% above its 52-week low of $0.065.
Summary
Audit Committee director Alexandra Peterson and Compensation Committee director Gabrielle Toledano both resigned effective October 14, 2026, shrinking Polomar's board from five to three. The company cites no disagreements and has not decided whether to fill the vacancies.
Key Events · Executive and Board Changes · PMHS
-
Two Directors Resign Same Day
Alexandra Peterson (Audit Committee) and Gabrielle Toledano (Compensation Committee) notified the board October 15, 2026 of resignations effective October 14, 2026.
-
Board Shrinks From Five to Three
The board reduced its size from five to three directors, leaving George Hornig, George Caruolo and Gabriel Del Virginia.
-
No Disagreement Cited
The company states neither resignation resulted from any disagreement on operations, policies or practices.
-
Vacancies Unresolved
The board has not determined whether to fill the two vacancies or further reduce its size.
Analysis · PMHS · Life Sciences
Losing 40% of the board at once, including audit oversight, is a governance concern for a micro-cap that previously disclosed going-concern doubt and material weakness in its controls. Two of five directors — one on the Audit Committee, one on the Compensation Committee — resigned effective October 14, leaving a three-person board with no replacements named. The company says there was no disagreement. The remaining directors are George Hornig, George Caruolo and Gabriel Del Virginia, and the board has not said whether it will fill the seats.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PMHS was trading at $0.12 on OTC in the Life Sciences sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $0.07 to $840,000.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.